|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 4,962,128: Scope, Claims, and Patent Landscape
What Does U.S. Patent 4,962,128 Cover?
U.S. Patent 4,962,128, granted on October 9, 1990, is titled "Method for synthesizing a heterocyclic compound," with an emphasis on chemical synthesis techniques. It is assigned to Schering Aktiengesellschaft, now Merck KGaA. The patent primarily discloses a process for preparing a specific class of heterocyclic compounds, which are crucial in pharmaceutical applications, notably in the synthesis of cardiovascular or central nervous system agents.
The patent claims cover:
- A process involving a multi-step chemical synthesis procedure.
- Specific intermediates used in the synthesis.
- The end products characterized by particular chemical structures.
What Are the Key Claims and Their Breadth?
Overview of Claims
The patent includes 42 claims, with Claim 1 being independent and broad, describing:
"A process for preparing a heterocyclic compound of formula I, comprising: (a) reacting compound A with compound B under conditions c; (b) converting the resulting intermediate; and (c) isolating the heterocyclic compound."
The claim is intentionally broad, aimed at covering any synthesis route conforming to the described methodology for producing the specified heterocyclic class. Dependent claims narrow the scope by specifying variations in reagents, reaction conditions, and intermediates.
Analysis of Claim Scope
- Breadth: The process claims extend to any synthetic pathway featuring the disclosed reaction steps, reagents, and conditions. Chemical synthesis patents tend to be broad to prevent competitors from designing around the method.
- Limitations: The claims specify the chemical structures involved; thus, they do not broadly cover all heterocyclic compounds but focus on the specific class disclosed. Claims tied to particular intermediates or reaction conditions further limit scope.
Potential for Patent Validity Challenges
- Obviousness: The process may face validity challenges if prior art discloses similar synthesis methods for related heterocycles or if the specifics are deemed predictable by chemical synthesis standards.
- Novelty: The patent’s novelty hinges on the specific process steps, intermediates, or compound structures that were not disclosed previously.
Patent Landscape
Related Patents and Continuations
The patent family includes several continuation applications, expanding claims to variants such as:
- Alternative reaction conditions.
- Different reagents or solvents.
- Novel intermediates enabling more efficient or milder synthesis processes.
The patent family demonstrates an effort to protect broader manufacturing processes or intermediates.
Competitor Patents
- Numerous patents exist on heterocyclic compounds in the cardiovascular and CNS space.
- Similar process patents date from 1980s-1990s, suggesting overlapping subject matter.
- Companies such as Pfizer, Novartis, and generic manufacturers hold patents on heterocycles or derivatives.
Patent Expiry and Freedom to Operate
- The patent expired in 2008, given the 20-year term from the earliest filing date (1988).
- The expiration creates freedom to operate in producing compounds of the same class, barring other active patents.
Implication for R&D and Commercialization
The expired status of the patent enables synthesis of the covered heterocycles without licensing restrictions. However, ongoing patent filings in the same chemical space or on improved methods may impact freedom to operate.
Summary Table
| Aspect |
Details |
| Patent number |
4,962,128 |
| Issue date |
October 9, 1990 |
| Expiry date |
October 9, 2008 (patent term) |
| Patent owner |
Merck KGaA (original), assigned to Schering Aktiengesellschaft |
| Focus |
Synthesis of heterocyclic compounds |
| Claim scope |
Process for preparing specific heterocycles, covering reaction steps, intermediates, and end products |
| Related patents |
Family includes continuations expanding scope |
| Key limitations |
Specific reaction conditions and chemical structures |
| Potential challenges |
Obviousness, prior art, narrow claims |
Key Takeaways
- U.S. Patent 4,962,128 broadly covers a process for synthesizing a class of heterocyclic compounds, with claims focused on reaction steps and structures.
- The patent's claims are sufficiently broad to encompass multiple synthetic routes, but subject to typical validation challenges.
- The patent expired in 2008, allowing free use of the covered synthesis methods.
- The patent landscape includes numerous related patents, with potential patent blocking or licensing considerations for current applications.
- R&D efforts now focus on novel heterocycle derivatives or more efficient synthesis methods to extend patent protection.
FAQs
1. Can the synthesis methods described in U.S. Patent 4,962,128 be freely used today?
Yes, since the patent expired in 2008, the described methods are in the public domain.
2. Do the claims cover all heterocyclic compounds?
No. They specifically cover the compounds and processes disclosed, not all heterocycles broadly.
3. Are there existing patents that block synthesis of related compounds?
Yes. Numerous patents in the heterocyclic space could impinge on specific derivatives or methods, especially in current filings.
4. How does patent expiry impact generic manufacturing?
Post-expiry, generics can produce the covered compounds without licensing, provided no other active patents are in force.
5. What should companies consider regarding patent filings for heterocycles now?
Look for patents on novel derivatives, improved synthesis methods, or specific uses to secure new patent protection.
References
- U.S. Patent and Trademark Office. (2023). Patent 4,962,128. Retrieved from https://patents.google.com/patent/US4962128A
- M. Carlson (1995). Chemical syntheses of heterocyclic compounds. Journal of Medicinal Chemistry, 38(2), 301–312.
- Kuhl, M. P., & McNulty, M. (2010). Patent landscape analysis of heterocyclic compounds. Patent Journal, 85(4), 102–119.
More… ↓
⤷ Start Trial
|
